Morfin DAK

Morphine Sulfate

Method of action: Analgesic, Antitussive, Hypnotic, Opioid

Treatment option: Insomnia, Pain, Cough, Dyspnea, Anxiety&Panic Attacks, Cancer, Heart Attack, Crush Injury, Surgery, Chronic Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Morfin DAK

Property	Description
Active ingredient	Morphine Sulfate
Form	Solution for injection/infusion
Pharmacological class	Opioid Analgesic
Common use	Powerful analgesia for severe pain
Origin	Naturally derived Opiate Alkaloid

What is Morfin DAK and Its Pharmacological Class?

Morfin DAK is a potent, prescription-only medication defined by its single active ingredient, Morphine Sulfate, which places it within the pharmacological class of Opioid Analgesics. Its primary purpose is the provision of powerful analgesia required for the clinical management of severe pain.

This substance functions as a pure Opioid Agonist and acts directly upon the central nervous system (CNS). The role of this medication is clinically recognized for addressing pain where weaker medications, such as common over-the-counter or less potent prescription relievers, are insufficient. As an Opioid Analgesic, it represents the strongest tier of pain management available, often used in scenarios like acute post-operative care.

Composition, Origin, and Pharmaceutical Form

The composition of Morfin DAK centers entirely on the International Nonproprietary Name (INN) substance, Morphine Sulfate. The base molecule, Morphine, is a naturally derived Opiate Alkaloid that originates from the opium poppy, Papaver somniferum.

The final medicinal product is designed as a single-component product and is supplied as a sterile, clear Solution for injection or infusion, formulated within an aqueous vehicle. This specific liquid format, intended for parenteral administration, differentiates it from oral tablet formulations of morphine. This specialized presentation allows for the immediate and controlled delivery of the Morphine Sulfate, which is essential in acute, severe pain settings requiring rapid intervention.

Regulatory References

MedlinePlus

What side effects are possible with Morfin DAK?

The official safety profile for Morfin DAK (Morphine Sulfate) is based on adverse reactions and safety constraints documented by government regulatory agencies (such as the FDA and EMA), which categorize risks by frequency and physiological system.

Adverse Reaction Scope

The most commonly reported adverse reactions are classified as Very Common (ge 1/10) and primarily involve the Gastrointestinal and Nervous Systems. These include nausea, vomiting, constipation, sedation, and drowsiness. Other Common effects (ge 1/100 to <1/10) listed in regulatory documents include headache, vertigo, and urinary retention.

Serious adverse reactions highlighted in official labeling are life-threatening respiratory depression, the potential for circulatory depression, and the inherent risks of addiction, abuse, and misuse. The risk of respiratory depression is documented as greatest during treatment initiation or following a dosage increase.

Safety Classifications and Special Populations

Time-Related Safety Patterns establish that the development of tolerance and physical dependence is associated with long-term use, and abrupt cessation can precipitate a drug withdrawal syndrome. The potential for Neonatal Opioid Withdrawal Syndrome is also officially noted when used during pregnancy.

Safety Restrictions define that the medication should not be used in conditions such as severe respiratory depression, acute bronchial asthma, or confirmed Paralytic Ileus. Official labeling also includes specific Population Safety Considerations for older adults and individuals with renal or hepatic impairment, noting they are at higher risk for prolonged or increased effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary and most serious risk associated with an overdose of morphine is serious, life-threatening, or fatal respiratory depression, which is the major cause of death in overdose situations. Overdose can occur from intentional misuse, medication errors (such as confusion between concentrations), or accidental ingestion.

Signs and Symptoms of Overdose

Official regulatory documents identify key clinical manifestations of overdose, which include:

Central Nervous System (CNS) Effects: Profound sedation, stupor, coma, and generalized CNS impairment.
Respiratory Effects: Abnormally slow, shallow, or weak breathing, which can progress to respiratory arrest.
Cardiovascular Effects: Circulatory depression, shock, and cardiac arrest.
Physical Signs: Pinpoint pupils and cold, clammy skin.

Factors That Increase Overdose Risk

Accidental ingestion of even a single dose, particularly by a child, can result in a fatal overdose and requires immediate emergency attention. The risk of profound sedation, respiratory depression, coma, and death is significantly increased when this medication is used concomitantly with alcohol, benzodiazepines, or other Central Nervous System depressants.

Emergency Action

Immediate medical help must be sought upon any suspected overdose. Due to the risk of life-threatening respiratory depression, resuscitative equipment and the specific opioid antagonist, naloxone, should be available. Prompt intervention is critical for managing the serious, life-threatening nature of the overdose profile.

Therapeutic Uses of Morfin DAK

What Morfin DAK Treats: Main Uses and Benefits

The primary therapeutic role of Morfin DAK is to provide supportive symptomatic relief for symptoms related to physical discomfort in situations where patients experience pronounced symptoms. It may be part of symptomatic management across contexts involving acute or chronic discomfort.

This medication is relevant for easing symptoms that interfere with daily functioning and is commonly used across conditions presenting with systemic or localized discomfort and heightened symptoms. It is applied in addressing symptom clusters that may become intense or disruptive, and it is relevant for managing symptoms that interfere with daily comfort, including in palliative care settings. It helps address symptoms that may appear suddenly or fluctuate, contributing to improved comfort during episodes where symptoms become temporarily overwhelming.

“This application supports patients during episodes of heightened discomfort.”

Morfin DAK helps address symptoms related to physical discomfort within palliative and end-of-life care, and contributes to improved comfort during symptomatic periods. It is commonly used to help with easing the overall symptom load.

Quick Fact: Relief for Severe Pain

Regulatory References

NIH StatPearls overview on Morphine

Eligibility and Restrictions for Use

This section explains the official population-eligibility and non-eligibility rules for Morfin DAK (Morphine Sulfate), as defined by authoritative governmental regulatory documents (e.g., FDA, EMA). Use is conditional upon the patient's existing health status and specific life stages.

Populations Who Must Not Use (Contraindications)

Classification	Eligibility Restriction
Respiratory	Individuals with significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting.
Gastrointestinal	Patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
Drug Interactions	Patients using Monoamine Oxidase Inhibitors (MAOIs) or who have used them within the last 14 days.
Allergy	Known hypersensitivity to morphine or any component of the product.

Eligibility Restrictions and Special Populations

Category	Official Regulatory Statement
Age Groups	Adults and Adolescents (ge 12 years) are generally eligible. Geriatric patients must be started on lower doses and monitored closely. Pediatric use requires careful titration, and some labels note that use in children under 12 is not recommended for certain forms.
Organ Function	Individuals with severe hepatic impairment or moderate/severe renal impairment are either formally contraindicated (as per some European regulators) or require significant caution and monitoring, due to the risk of drug accumulation.
Reproductive Status	Pregnancy carries the labeled risk of Neonatal Opioid Withdrawal Syndrome (NOWS) with prolonged use, and this risk must be communicated. Use during lactation is generally not recommended by regulatory bodies.
Clinical Status	Use should be avoided in patients with increased intracranial pressure, head injury, impaired consciousness, or circulatory shock. Caution is required for patients with COPD or a history of substance use disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Morfin DAK interactions are officially documented across several categories, primarily focusing on pharmacodynamic reinforcement and pharmacokinetic exposure modification, as defined by regulatory authorities.

Interaction Classification	Interacting Agent(s)	Official Documented Outcome
Formally Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Use is prohibited, including within 14 days of MAOI cessation.
Profound Risk	CNS Depressants & Alcohol	Additive effects leading to severe respiratory depression, profound sedation, coma, and death.
Exposure Modification	Rifampicin & Cimetidine	Rifampicin reduces plasma concentrations; Cimetidine may increase exposure and CNS effects.
Efficacy Interference	Oral P2Y12 Inhibitors	Documented reduced efficacy of the antiplatelet medicine, particularly noted during the first day.
Pharmacodynamic	Serotonergic Drugs	Concomitant use carries a documented risk of Serotonin Syndrome.

Interaction-Related Restrictions and Constraints

Regulatory documents mandate restrictions on co-administration, specifically contraindicating the combination with MAOIs. Co-administration with Mixed Agonist/Antagonist Opioids (e.g., Pentazocine) is avoided due to the potential for reduced pain relief or precipitated withdrawal. The additive effects with Anticholinergic Drugs may also increase the risk of severe paralytic ileus and urinary retention. In patients with Hepatic or Renal Impairment, the official labeling notes that the effects of the medicine may be increased due to slower removal from the body, which dictates a need to account for altered interaction risk.

Mechanism of Action

Morfin DAK acts primarily through its high-affinity binding to the mu-opioid receptors (MOR), which are inhibitory G-protein coupled receptors (Gi/ o) localized throughout the central nervous system (CNS), including the spinal cord and brainstem. The binding event initiates the primary molecular action of the compound. Following agonist binding, the MOR undergoes a conformational change, leading to the activation and dissociation of the heterotrimeric G-protein complex. The released Galpha subunit subsequently inhibits the enzyme adenylyl cyclase (AC), resulting in a reduction of intracellular cyclic AMP (cAMP) production. Concurrently, the Gbetagamma subunit opens voltage-gated potassium channels (K^+ channels). The influx of K^+ ions leads to neuronal hyperpolarization, making the post-synaptic neuron less responsive to excitatory stimuli. This cascade ultimately results in the pre-synaptic inhibition of calcium ion influx, thereby decreasing the release of various excitatory neurotransmitters, including Substance P and acetylcholine, across afferent pathways. This is the physiological basis of the compound's effect.

Dosage and Administration Information

How to Use Morfin DAK — Official Administration Guidelines

The administration of Morfin DAK (morphine sulfate) must strictly follow official guidelines to ensure safety and effectiveness. The dosage and route are highly individualized based on the patient's condition and prior analgesic experience. The official procedure emphasizes starting with the lowest effective dosage for the shortest duration necessary for treatment goals.

Administration Details

Classification	Rule/Dosing Summary
Route of Administration	Most common routes include Intravenous (IV), Intramuscular (IM), and Oral (solution, immediate-release, or extended-release tablets).
Adult Initial Dosing	IV Injection: 0.1 mg to 0.2 mg per kg, administered slowly, typically every four hours as needed. Oral Solution/Tablets: 10 mg to 30 mg every four hours as needed for pain, for opioid-naïve adults.
Preparation Requirements	Injectable solutions must be inspected for particulate matter or discoloration before use. The high-concentration oral solution requires the use of a calibrated oral syringe for accurate measurement.

Special Procedural Conditions

Dose Individualization and Titration: The dosing regimen must be initiated individually, and the dose should be titrated slowly based on the patient's response. Dosage adjustment is critical for geriatric patients and those with hepatic or renal impairment, who should begin at the low end of the dosing range.
Administration Technique (IV): Intravenous injection must be administered slowly to minimize the risk of adverse effects such as chest wall rigidity and delayed Central Nervous System (CNS) effects. Rapid administration is discouraged.
Discontinuation: The medication should not be abruptly discontinued in a physically dependent patient. The dose must be gradually tapered by 25% to 50% every two to four days while monitoring for signs of withdrawal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Morfin DAK

Evidence for Use in Severe Acute and Chronic Pain

The research base for Morfin DAK includes foundational Randomized Controlled Trials (RCTs) and comparative effectiveness studies that examined how symptoms change over time. These studies were applied in contexts where patients experienced outcomes related to physical discomfort that required intervention. The studies monitored patient-reported outcomes describing perceived discomfort and tracked measures of activity level. Research describes that Morfin DAK was studied in comparison with other pain medications. A key limitation is the absence of new, large-scale, placebo-controlled RCTs for acute severe pain, leading regulatory bodies to rely heavily on long-established evidence. There is limited information for long-term outcomes regarding daily functioning when the medication is applied for chronic non-cancer pain.

Research Context for Pain in Advanced Disease (Palliative Care)

For conditions associated with acute or disruptive episodes, such as pain related to advanced disease, the evidence is summarized within Systematic Reviews and Meta-analyses. Studies primarily explored how symptoms evolved in patients with conditions where symptoms may vary in intensity. The main outcomes research examined include the proportion of patients whose symptoms reached a predefined level of reported comfort. A significant limitation is that the evidence quality varies across studies, with many underlying trials based on small sample sizes and limited follow-up durations (e.g., two weeks).

Evidence in Special Populations and Research Gaps

Research examined the use of Morfin DAK in special populations, specifically pediatric patients and older adults. For pediatric populations, the substance was evaluated in children through studies of the medication in this population used in research exploring how symptoms change over time. Data for subgroups, including older adults, remain insufficient, and comparative evidence is lacking. The overall evidence base is categorized as an Established Standard, but a scrutiny of individual trials reveals limitations in sample size and long-term functional outcomes. The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Morfin DAK (FAQ)

Q: Can Morfin DAK affect my ability to drive or operate machinery?

Official documents state that Morfin DAK can cause common side effects such as drowsiness, dizziness, and sedation. These effects may impact a person’s ability to drive, operate machinery, or perform tasks that require alertness. Regulatory documents recommend that individuals avoid these activities until they understand how the medicine affects their alertness.

Q: Is it normal to feel a little dizzy when first starting Morfin DAK?

Dizziness is a commonly reported side effect described in official product information. This feeling, known as orthostatic hypotension, often occurs when a person stands up too quickly from a sitting or lying position. It may be a more noticeable experience when initiating therapy.

Q: Does Morfin DAK cause constipation, and if so, how is it typically managed?

Constipation is noted as a very common side effect officially associated with Morfin DAK. Because this is a specific type of constipation, official protocols describe that management often involves the use of certain types of laxatives. Protocols suggest that increasing dietary fiber or water intake alone is generally insufficient for opioid-related constipation.

Q: Does Morfin DAK affect blood pressure?

Yes, official information indicates that Morfin DAK can affect the circulatory system. It may cause peripheral vasodilation (widening of blood vessels) and lead to orthostatic hypotension. This drop in blood pressure can occur, particularly when changing position.

Q: How long does it typically take for official side effects to disappear after stopping Morfin DAK?

The duration of side effects is described as depending on the formulation used and the drug’s processing time within the body. Formulations designed for longer release may have effects that persist for a period after the final dose, which is consistent with the drug’s half-life.

Q: How does Morfin DAK compare to other opioid medicines in official descriptions?

Official sources describe Morfin DAK (morphine) as a natural opioid that functions primarily as an agonist at the mu-opioid receptor. Specialized medical guidelines contain comparative tables that describe the relative strength or potency of other opioid medicines compared to morphine.

Q: What is the main reason a doctor would prescribe Morfin DAK?

Morfin DAK (morphine) is officially prescribed to relieve severe pain. As an opiate analgesic, it is used to change how the brain and nervous system perceive pain signals, providing relief where other treatments may be insufficient.

Q: Is Morfin DAK considered a strong pain reliever?

Yes, Morfin DAK (morphine) is officially described as a potent opioid analgesic. It is often designated as a Step III (strong) medicine within international pain management guidelines, such as the World Health Organization's analgesic ladder.

Q: How quickly does Morfin DAK start to work after taking it?

Official information indicates that for oral forms of Morfin DAK, the peak analgesic effects are typically reached approximately 60 minutes after the dose is taken.

Q: What is the typical length of time Morfin DAK is active in the body?

The duration of activity is dependent on the formulation. Immediate-release forms are typically prescribed with a four-hour interval. Extended-release forms are specifically designed to provide a longer effect, often lasting 12 or 24 hours for continuous pain management.

Q: Is Morfin DAK the same as regular morphine?

Morfin DAK is a specific brand name for a medicine whose active ingredient is morphine sulfate. 'Regular morphine' generally refers to the generic substance (morphine) or its immediate-release formulation, which may be made by various companies.

Q: Are there different types or formulations of Morfin DAK?

Yes, official documents confirm that the medicine is available in various forms. These can include oral solutions, immediate-release tablets, extended-release tablets, and specific formulations designed for injection.

Q: What should I do if I miss a scheduled dose of Morfin DAK?

General protocols for scheduled opioid therapy often advise against taking an extra dose to compensate for a missed one. Patients are usually guided to resume their regular schedule with the next planned dose. Specific instructions must be followed as provided by the prescriber.

Q: Are there any common foods or drinks to avoid while using Morfin DAK?

Official warnings emphasize that consuming alcohol or medications that contain alcohol must be avoided due to the severe risk of side effects. Some regulatory-cited studies also suggest that a high-fat meal may affect the amount of medicine absorbed.

Q: Can Morfin DAK be taken with common over-the-counter pain medicines?

Official guidance generally indicates that taking Morfin DAK with common over-the-counter (OTC) pain relievers, such as paracetamol or ibuprofen, is usually permitted. Regulatory guidance suggests reviewing the ingredients of all OTC medicines, especially those that contain codeine, as co-administration with other opioid-type medicines is generally avoided.

Q: Is Morfin DAK appropriate for use in older adult patients?

Official documents indicate that Morfin DAK can be used in older adults, but specific considerations apply. Older patients are recognized as being at a higher risk for increased or prolonged effects, and official documentation notes that treatment should be initiated at the low end of the dosing range.

Q: Does Morfin DAK have any known interactions with herbal supplements?

Due to a lack of formal testing, regulatory guidance cannot confirm that all herbal remedies or supplements are safe to use with Morfin DAK. Patients are advised that certain supplements, particularly those that may cause drowsiness, could increase the risk of central nervous system (CNS) side effects.

Q: Can Morfin DAK be used for pain that comes and goes (breakthrough pain)?

Yes, the short-acting or immediate-release forms of Morfin DAK are commonly used in specialized guidelines to manage breakthrough pain. This refers to the unexpected, temporary increase in pain that can occur even in patients who are already receiving scheduled pain medicine.

Q: Can people with a history of substance use disorder take Morfin DAK?

Official labeling requires prescribers to assess every patient for their risk of addiction, including those with a personal or family history of substance abuse. Prescribing the medicine to such individuals is associated with regulatory requirements for close monitoring and reevaluation for signs of misuse.

Q: What is the difference between immediate-release and extended-release Morfin DAK?

Immediate-release forms are designed to provide rapid pain relief, with the effect lasting a shorter period. Extended-release forms are formulated to release the active ingredient slowly over many hours, aiming to provide a longer-lasting, continuous level of pain management.

Q: What common non-prescription medicines should be checked for interactions with Morfin DAK?

Patients are generally advised to check for ingredients in non-prescription medicines that could overlap with or enhance Morfin DAK's effects. This includes products containing codeine or other opioid-related compounds, and any medicine that causes drowsiness or contains alcohol.

Q: Can Morfin DAK be taken before or after a meal?

Regulatory-cited studies suggest that taking oral Morfin DAK immediately after a meal, especially a high-fat meal, may increase the total amount of medicine absorbed by the body. Taking it while fasting may result in a different level of absorption.

Q: Can Morfin DAK affect my mood or cause mood changes?

Official product documentation lists mental depression, confusion, and disorientation as possible side effects. The therapeutic effect of the medicine is known to include sedation and anxiolysis (the reduction of anxiety).

Q: Are there specific age limits described for using Morfin DAK?

The official label addresses specific use in both pediatric patients (children) and older adults. While a single, fixed minimum age limit is not universally stated, official guidance requires individualized dosing for children, and cautionary direction is provided for older adults.

Q: Are there any special warnings for people with breathing problems using Morfin DAK?

Official warnings state that the medicine is contraindicated (should not be used) in patients with severe respiratory depression or acute bronchial asthma. Caution is also advised for individuals with other breathing problems, as the medicine may increase the risk of serious side effects.

Q: Is Morfin DAK recommended for use during pregnancy or breastfeeding?

Official labeling notes that using the medicine during pregnancy carries a risk of Neonatal Opioid Withdrawal Syndrome in the infant. The medicine is also known to be excreted in breast milk. Use during pregnancy or breastfeeding is typically considered when the potential benefit is described as outweighing the potential risks to the fetus or infant.

Q: What are the ingredients in Morfin DAK besides the active substance?

Official product documentation, such as the Summary of Product Characteristics (SmPC), lists all ingredients, including the active substance (morphine sulfate) and all excipients (inactive ingredients). These excipients may include substances like lactose, specific coatings, or colorants.

Q: Is Morfin DAK typically prescribed for non-cancer related pain?

Official documents state the medicine is indicated for severe pain that is not relieved by other treatments. Research evidence has been specifically gathered and examined regarding its use for chronic non-cancer pain, which informs prescription practices.

Q: What is the meaning of the DAK in Morfin DAK?

DAK is a historical component of the brand name of the medicine. It is not a medical term but is associated with the original manufacturer or distributor, such as DAK-Laboratoriet A/S, which produced the product.

Q: What is the official classification of Morfin DAK regarding controlled substances?

Morfin DAK (morphine) is officially classified as a Schedule II controlled substance by regulatory bodies in the United States, such as the DEA. This classification is assigned to medicines with a high potential for abuse but which also have recognized medical uses.

How should Morfin DAK be stored and disposed of?

Storage and Disposal Requirements

Regulatory labeling dictates specific conditions for storing and disposing of Morfin DAK (Morphine Sulfate 10 mg/ml solution for injection).

Category	Official Regulatory Requirements
Storage Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permissible excursions.
Protection	Must be kept in the original outer carton to protect the contents from light. The solution should not be used if discoloration or particulate matter is observed.
Child Safety	Store securely and out of the sight and reach of children due to the risk of accidental fatal overdose.
Stability	The product is for single use only; any remaining solution must be discarded immediately after use.
Disposal	Dispose of any unused medicinal product or waste material in accordance with local requirements for pharmaceutical waste.